<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395784</url>
  </required_header>
  <id_info>
    <org_study_id>6106</org_study_id>
    <secondary_id>R01DA09236</secondary_id>
    <nct_id>NCT01395784</nct_id>
  </id_info>
  <brief_title>Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone</brief_title>
  <official_title>Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been
      characterized in a controlled laboratory setting. Accordingly, the proposed investigation
      seeks to examine the effects of PIO on oxycodone, one of the most commonly used and abused
      opioid drugs in the U.S. (Davis et al., 2003). More specifically, the primary aim of this
      investigation is to characterize the subjective effects of oxycodone under maintenance on
      various doses of PIO (0, 15, and 45 mg) in non-dependent, prescription opioid abusers.
      Secondary aims of the study are to examine the influence of PIO on the analgesic, cognitive,
      and physiological effects of oxycodone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 9-week investigation will use an inpatient/outpatient design in which participants will
      be maintained on ascending doses of pioglitazone (3 weeks on placebo followed by 3 weeks on
      PIO 15 mg followed by 3 weeks on PIO 45 mg). At the end of each maintenance period the
      effects of oxycodone (0, 10, and 20 mg) will be examined during a single laboratory session
      using a cumulative dosing procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Ratings of &quot;Good&quot; Drug Effect</measure>
    <time_frame>Measured during the lab session conducted at the end of each maintenance period</time_frame>
    <description>Visual analog scale ratings (0-100 mm scale, 0=Not at all, 100=Extremely)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic Responses Using the Cold Pressor Test</measure>
    <time_frame>Measured during the lab session conducted at the end of each maintenance period</time_frame>
    <description>Latency to withdraw hand from cold water during the cold pressor test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>Placebo Maintenance Period</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIO 15 Maintenance Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIO 45 Maintenance Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.</description>
    <arm_group_label>Placebo Maintenance Period</arm_group_label>
    <arm_group_label>PIO 15 Maintenance Period</arm_group_label>
    <arm_group_label>PIO 45 Maintenance Period</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recreational use of prescription opioids at least once per month within the past year

          2. No current major mood, psychotic, or anxiety disorder

          3. Physically healthy

          4. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) within normal
             limits

          5. Able to perform study procedures 6.21-45 years of age

        7.Blood glucose concentration between 70-145 mg/dl for men and 70-125 mg/dl for women
        (fasting) 8.Hb &gt; 13 for men and Hb &gt; 11 for women with no other evidence of medical
        disorder resulting in blood loss or anemia/hematological disease

        Exclusion Criteria:

          1. Physical dependence on any drugs, excluding nicotine and caffeine

          2. Participants requesting treatment

          3. Participants on parole or probation

          4. Pregnancy or lactation: Female participants must agree to the use of a barrier control
             method of contraception (e.g. male and female condoms, diaphragms, cervical caps and
             contraceptive sponges used in combination with spermicide)

          5. Current or recent history of significant violent behavior (within the past 6 months)

          6. Current major Axis I psychopathology that might interfere with ability to participate
             in the study

          7. Significant suicide risk

          8. Current chronic pain

          9. Current or history of congestive heart failure, edema, or diabetes mellitus

         10. Sensitivity, allergy, or contraindication to opioids or pioglitazone

         11. Unstable physical disorders that might make participation hazardous, such as end-stage
             AIDS, hypertension (blood pressure &gt; 140/90), or heart disease (please note that
             participants will be asked about previous visits to a cardiologist, chest pain, or
             strong palpitations; if these exist, they will be referred to a cardiologist and
             excluded unless cleared for participation by a cardiologist)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra D Comer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia Univ/ NYSPI Division on Substance Abuse</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <results_first_submitted>August 31, 2015</results_first_submitted>
  <results_first_submitted_qc>January 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2016</results_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxycodone</keyword>
  <keyword>Opioid abuse</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data has been presented at conferences and being prepared for a peer-review publication.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Withing-subjects, Placebo-Controlled</title>
          <description>Participants will complete the various outcome measures following maintenance period of: Placebo, Pioglitazone 15 mg, and 45 mg.
pioglitazone: A PPARγ agonist, also marketed as Actos.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Recreational prescription opioid users.</population>
      <group_list>
        <group group_id="B1">
          <title>Withing-subjects, Placebo-Controlled</title>
          <description>Participants will complete the various outcome measures following maintenance period of: Placebo, Pioglitazone 15 mg, and 45 mg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Ratings of &quot;Good&quot; Drug Effect</title>
        <description>Visual analog scale ratings (0-100 mm scale, 0=Not at all, 100=Extremely)</description>
        <time_frame>Measured during the lab session conducted at the end of each maintenance period</time_frame>
        <population>Shown below are peak drug effects from each of the 3 maintenance periods (Placebo, Pioglitazone (PIO) 15, and PIO 45)</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants will complete the various outcome measures following maintenance period of: Placebo, Pioglitazone 15 mg, and 45 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ratings of &quot;Good&quot; Drug Effect</title>
          <description>Visual analog scale ratings (0-100 mm scale, 0=Not at all, 100=Extremely)</description>
          <population>Shown below are peak drug effects from each of the 3 maintenance periods (Placebo, Pioglitazone (PIO) 15, and PIO 45)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIO 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIO 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Responses Using the Cold Pressor Test</title>
        <description>Latency to withdraw hand from cold water during the cold pressor test.</description>
        <time_frame>Measured during the lab session conducted at the end of each maintenance period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants will complete the various outcome measures following maintenance period of: Placebo, Pioglitazone 15 mg, and 45 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Responses Using the Cold Pressor Test</title>
          <description>Latency to withdraw hand from cold water during the cold pressor test.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIO 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIO 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed daily throughout the study.</time_frame>
      <desc>A study nurse queried participants concerning any adverse events using the Systematic Assessment for Treatment Emergent Events (SAFTEE)</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Participants will complete the various outcome measures following maintenance period of: Placebo, Pioglitazone 15 mg, and 45 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jermaine Jones, PhD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646 774-6113</phone>
      <email>jonesje@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

